Title: Microbiota, Immunology and Vaccines to tackle antimicrobial resistance

Biography:

Ivana Haluskova Balter is a French Medical professional specialized in infectious diseases, internal medicine covering various therapeutic axes, certified in Immunology and Pediatric, MBA vaccinology and years of active clinical practice.Lived multi-country medical “field “experience in Southeast Asia (India in particular), West/Central/East Europe.

Abstract

Bacteria, viruses, parasites and fungi that are resistant to drug cause 700,000 death each year. By 2050 superbugs inured to treatments could cause up to 10 million deaths annually and costs the global economy US$100 trillion.AMR(antimicrobial) resistance is regarded nowadays as a major threat to global public health. The issue is receiving high-level political attention (G7 and G20 in 2017 for first time). Pandemics, drug resistance and neglected diseases framing health as a “global security issue”.The list was drawn up in a bid to guide and promote research and development (R&D) of new antibiotics, as part of WHO’s efforts  for AMR (27th Feb 2017)

Tuberculosis (MDR/XDR) and latent tuberculosis represent a major issue to tackle attracts global attention as witnessed by recent WHO and inter-ministerial meeting in November 2017 and high level UN meeting which have been hold in September 2018.Problem of resistance get worsened due declining number of new antibiotics and limited number of new classes. Antibiotic use influence composition of microbiota in  each individual. Similar trends are seen in drug development and use for  treatment of tuberculosis.